Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Baricitinib reduces inflammation and improves cell health in premature aging cells.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Somatic BHD mutations are rare in Japanese renal tumors.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Upadacitinib effectively treats psoriasis and lichen planus together.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.